An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

The duration of treatment is 7 days.

Inclusion Criteria:

• Males and females (ages 25-75)

Exclusion Criteria:

• A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study